Title
No effect of unfractioned or low molecular weight heparin treatment on markers of vascular wall and hemostatic function in incipient diabetic nephropathy
Author
Myrup, B.
Jensen, T.
Gram, J.
Kluft, C.
Jespersen, J.
Deckert, T.
Gaubius Instituut TNO
Publication year
1997
Abstract
OBJECTIVE - The high risk for cardiovascular disease in IDDM patients with nephropathy may be mediated by abnormal function of the vascular wall. We investigated whether heparin was able to modulate markers of vascular wall and hemostatic function in patients with incipient nephropathy. RESEARCH DESIGN AND METHODS - Thirty-five IDDM patients with incipient nephropathy were randomized to treatment with placebo, unfractioned heparin, or low molecular weight heparin in a double-blind trial. The treatment was given as 1 h of conventional intravenous high-dose treatment and in a conventional subcutaneous low-dose regime for 3 months. Transcapillary escape rate of albumin and plasma levels of von Willebrand factor, fibrinogen, prothrombin fragment 1 + 2, thrombin-antithrombin III complexes, tissue type plasminogen activator, tissue plasminogen activator inhibitor type 1, total cholesterol, HDL cholesterol, and triglycerides were measured before and after treatment. Of the patients, 31 completed the study. RESULTS - We found no significant effect of heparin on markers of vascular wall and hemostatic function by any of the treatments. CONCLUSIONS - Treatment with high- or low-dose heparin induced no modulation of markers of vascular wall or hemostatic function in IDDM patients with incipient diabetic nephropathy.
Subject
Biology
Biological marker
High density lipoprotein cholesterol
Insulin
Low molecular weight heparin
Placebo
Plasminogen activator inhibitor 1
Prothrombin
Sodium chloride
Thrombin
Tinzaparin
Blood clotting
Blood vessel wall
Cardiovascular disease
Clinical article
Clinical trial
Controlled clinical trial
Controlled study
Diabetic nephropathy
Double blind procedure
Drug effect
Hemostasis
Insulin dependent diabetes mellitus
Intravenous drug administration
Randomized controlled trial
Subcutaneous drug administration
Adult
Albuminuria
Antithrombin III
Capillaries
Cardiovascular Diseases
Cholesterol
Cholesterol, HDL
Diabetes Mellitus, Type 1
Diabetic Angiopathies
Diabetic Nephropathies
Double-Blind Method
Female
Fibrinogen
Hemostasis
Heparin
Heparin, Low-Molecular-Weight
Humans
Male
Middle Aged
Muscle, Smooth, Vascular
Peptide Fragments
Peptide Hydrolases
Placebos
Plasminogen Activator Inhibitor 1
Protein Precursors
Prothrombin
Tissue Plasminogen Activator
Triglycerides
von Willebrand Factor
To reference this document use:
http://resolver.tudelft.nl/uuid:8ca5ca65-457c-468b-a47b-e778c6bbdc43
TNO identifier
234062
ISSN
0149-5992
Source
Diabetes Care, 20 (10), 1615-1619
Document type
article